Based on the MPH Health Care AG stock forecast from 0 analysts, the average analyst target price for MPH Health Care AG is not available over the next 12 months. MPH Health Care AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MPH Health Care AG is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, MPH Health Care AG’s stock price was EUR 21.00. MPH Health Care AG’s stock price has changed by -1.87% over the past week, -6.67% over the past month and +39.53% over the last year.
No recent analyst target price found for MPH Health Care AG
No recent average analyst rating found for MPH Health Care AG
Company Overview MPH Health Care AG
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany. Address: GrUenauer Strasse 5, Berlin, Germany, 12557 Read Less
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceut...Read More
Frequently Asked Questions About MPH Health Care AG (93M1:XETRA) Stock
Stock Target Advisor's fundamental analysis for MPH Health Care AG's stock is Slightly Bullish .
Unfortunately we do not have enough data on 93M1:XETRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 93M1:XETRA's stock to indicate what its average analyst target is.
93M1:XETRA stock's Price/Earning ratio is 1.79.
Our analysis grades 93M1:XETRA stock's Price / Earning ratio at A+. This means that 93M1:XETRA stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the XETRA exchange.
Based on this 93M1:XETRA may be undervalued for its sector.
The last closing price of 93M1:XETRA's stock was EUR 21.00.
The most recent market capitalization for 93M1:XETRA is EUR 0.09B.
Unfortunately we do not have enough analyst data on 93M1:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MPH Health Care AG's stock.
As per our most recent records MPH Health Care AG has 1 Employees.
MPH Health Care AG's registered address is GrUenauer Strasse 5, Berlin, Germany, 12557.
You can get more information about it from MPH Health Care AG's website at https://www.mph-ag.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 93M1:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
